Kristy Wood, PhD

SVP, Technical Operations at Intellia Therapeutics

Speaker

Kristy Wood oversees process and analytical development, and internal manufacturing for Intellia’s gRNA, mRNA, LNP, AAV, cell therapy and small molecule platforms. Kristy joined Intellia in 2017 and was initially responsible for developing Intellia’s LNP platform and overseeing delivery technologies for therapeutic applications of CRISPR/Cas9. Kristy has more than 18 years of industrial experience in developing novel drug delivery systems for the delivery of nucleic acids and proteins. Her interest in nucleic acid delivery began as a scientist at Baxter Healthcare and has led her to work on projects to deliver ASO, siRNA, and mRNA through various routes of administration across many therapeutic areas. Kristy has been involved in small-scale formulation development, process scale-up and analytical characterization, and tech transfers moving drug substance and drug product processes from research into clinical manufacturing. Prior to Intellia, she was focused on the manufacturing and delivery of mRNA as a therapeutic using lipid nanoparticle delivery systems at Moderna, Pfizer, and Shire. Kristy has been issued a number of U.S. patents in the RNA & LNP fields. She received her Ph.D. in Biomedical Engineering from the University of Texas at Austin and her B.S. in Biomedical Engineering from the University of Wisconsin-Madison.